![](https://news.europawire.eu/wp-content/uploads/2014/04/Gedeon-Richter.jpg)
Budapest and New York, 1-4-2014 — /EuropaWire/ — Gedeon Richter Plc. and Forest Laboratories, Inc. (NYSE: FRX) today announced positive topline results from a Phase IIb trial evaluating the efficacy and safety of the investigational antipsychotic cariprazine in patients with bipolar depression. … Read the full press release